3005-1452

npj Drug Discovery

Springer Science and Business Media LLC

View prefix report (10.1038)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 53 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact53 DOIs
2

Add abstracts to 33 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact33 DOIs
3

Deposit reference lists for 1 record

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact1 DOIs

DOIs for this ISSN

Showing the top 5 of 53 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Structure and dynamics in drug discovery (10.1038/s44386-024-00001-2)
Abstract ORCID
92.56 70
2 Recent advances in molecular representation methods and thei… (10.1038/s44386-025-00017-2)
Abstract ORCID
69.01 23
3 AI meets physics in computational structure-based drug disco… (10.1038/s44386-025-00019-0)
Abstract ORCID
63.94 18
4 Integrating artificial intelligence into small molecule deve… (10.1038/s44386-025-00029-y)
Abstract ORCID
62.76 17
5 Synthesis and characterization of soquelitinib a selective I… (10.1038/s44386-024-00002-1)
Abstract ORCID
60.21 15
6 Evaluation of DNA encoded library and machine learning model… (10.1038/s44386-025-00007-4)
Abstract ORCID
60.21 15
7 Augmented BindingNet dataset for enhanced ligand binding pos… (10.1038/s44386-024-00003-0)
Abstract ORCID
58.80 14
8 FeatureDock for protein-ligand docking guided by physicochem… (10.1038/s44386-025-00005-6)
Abstract ORCID
55.70 12
9 Navigating structure-based drug discovery with emerging inno… (10.1038/s44386-025-00031-4)
Abstract ORCID
55.70 12
10 Understanding the molecular insights of marketed liposomal d… (10.1038/s44386-025-00014-5)
Abstract ORCID
53.96 11
11 Intracellular GPCR modulators enable precision pharmacology (10.1038/s44386-025-00011-8)
Abstract ORCID
47.71 8
12 Therapeutic safety implications of SARM1 active site inhibit… (10.1038/s44386-025-00023-4)
Abstract ORCID
47.71 8
13 Challenges and opportunities in computational studies for li… (10.1038/s44386-025-00024-3)
Abstract ORCID
42.25 6
14 Quantum-machine-assisted drug discovery (10.1038/s44386-025-00033-2)
Abstract ORCID
34.95 4
15 The AI drug revolution needs a revolution (10.1038/s44386-025-00013-6)
Abstract ORCID
30.10 3
16 Development of potent, selective cPLA2 inhibitors for target… (10.1038/s44386-025-00035-0)
Abstract ORCID
30.10 3
17 AI-guided competitive docking for virtual screening and comp… (10.1038/s44386-026-00039-4)
Abstract ORCID
30.10 3
18 Revisiting the Plasmodium falciparum druggable genome using… (10.1038/s44386-025-00006-5)
ORCID
25.00 9
19 Predicting drug combination response surfaces (10.1038/s44386-024-00004-z)
ORCID
23.86 8
20 SARM1 base-exchange inhibitors induce SARM1 activation and n… (10.1038/s44386-025-00016-3)
ORCID
23.86 8
21 Mechanisms that matter: unbiased cellular screening for degr… (10.1038/s44386-025-00028-z)
Abstract ORCID
23.86 2
22 Discovery of a small molecule secreted clusterin enhancer th… (10.1038/s44386-025-00009-2)
ORCID
22.58 7
23 Author Correction: The AI drug revolution needs a revolution (10.1038/s44386-025-00022-5)
Abstract References ORCID
22.58 1
24 Drugging Ras trafficking—are there new roads to travel? (10.1038/s44386-025-00012-7)
ORCID
21.13 6
25 Structural and mechanistic study of a novel inhibitor analog… (10.1038/s44386-025-00008-3)
ORCID
15.05 3
26 An online GPCR drug discovery resource (10.1038/s44386-025-00010-9)
ORCID
15.05 3
27 The antibody-peptide fusion protein, AT-02, is an effective… (10.1038/s44386-025-00015-4)
ORCID
15.05 3
28 Intranasal monoclonal antibodies do not prevent respiratory… (10.1038/s44386-025-00018-1)
Abstract ORCID
15.05 1
29 Advancements in RNA-based therapies from bench to bedside (10.1038/s44386-025-00037-y)
ORCID
15.05 3
30 A Metabolism-Informed Neural Network Identifies Pathways Inf… (10.1038/s44386-026-00042-9)
Abstract ORCID
15.05 1
31 Innovation breakthrough in the Alzheimer’s disease pharmaceu… (10.1038/s44386-026-00044-7)
Abstract ORCID
15.05 1
32 Genetic evidence informs the direction of therapeutic modula… (10.1038/s44386-025-00027-0)
ORCID
11.93 2
33 A review of deep learning approaches for drug synergy predic… (10.1038/s44386-025-00034-1)
ORCID
11.93 2
34 Preclinical characterization of EGT710, an oral non-peptidom… (10.1038/s44386-025-00030-5)
ORCID
7.53 1
35 A systems-level machine learning approach uncovers therapeut… (10.1038/s44386-025-00036-z)
ORCID
7.53 1
36 Interaction-constrained 3D molecular generation using a diff… (10.1038/s44386-026-00040-x)
ORCID
7.53 1
37 Vector venom: venomics of Aedes albopictus reveals a large e… (10.1038/s44386-026-00041-w)
ORCID
7.53 1
38 Cystobactamid off-target profiling reveals favorable safety,… (10.1038/s44386-025-00020-7)
ORCID
0.00 0
39 Phenotypic similarity of adverse drug reactions and disease… (10.1038/s44386-025-00021-6)
ORCID
0.00 0
40 Mechanistic basis for a novel dual-function Gag-Pol dimerize… (10.1038/s44386-025-00025-2)
Abstract ORCID
0.00 0
41 A novel drug series optimized to address cystic fibrosis and… (10.1038/s44386-025-00026-1)
Abstract ORCID
0.00 0
42 A genetics-guided integrative framework for drug repurposing… (10.1038/s44386-025-00032-3)
Abstract ORCID
0.00 0
43 Preferential HER4 stimulation preserves neuregulin-induced i… (10.1038/s44386-026-00038-5)
Abstract ORCID
0.00 0
44 Large animal models for the assessment of snakebite envenomi… (10.1038/s44386-026-00043-8)
ORCID
0.00 0
45 Deep learning-driven integrated pipeline for de novo design… (10.1038/s44386-026-00045-6)
Abstract ORCID
0.00 0
46 Accelerating GPCR drug discovery through computation and exp… (10.1038/s44386-026-00046-5)
Abstract ORCID
0.00 0
47 MAMMAL - Molecular Aligned Multi-Modal Architecture and Lang… (10.1038/s44386-026-00047-4)
ORCID
0.00 0
48 Assessing the ligand native-like pose using a quantum mechan… (10.1038/s44386-026-00048-3)
Abstract ORCID
0.00 0
49 Mechanistic and therapeutic insights into class A GPCR dimer… (10.1038/s44386-026-00049-2)
Abstract ORCID
0.00 0
50 Spider venom peptides Ht1a and Gg1a are toxic to honeybee pa… (10.1038/s44386-026-00050-9)
ORCID
0.00 0